not responding to semaglutide GLP-1 Resistance: Why Some Patients Don't Respond 7 Reasons Why You're Not

Osteoarthritis: weight + pain In people with obesity and knee osteoarthritis , once-weekly semaglutide 2.4 mg produced: Greater weight loss Significantly larger reductions in knee pain Improved function Obstructive sleep apnea (OSA) The SURMOUNT-OSA phase 3 trials showed that tirzepatide (Zepbound) in adults with obesity and moderate-to-severe OSA: Reduced the apneahypopnea index (AHI) Lowered body weight, hypoxic burden, hsCRP, and systolic BP Improved sleep-related patient-reported outcomes compared with placebo In December 2024, the FDA approved Zepbound as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity , alongside diet and physical activity

PlexusDx recommends using your abdomen, upper arm, and thigh in a planned sequence, waiting at least 7 days before returning to the same spot

LegitScript certified, month-to-month billing

You now draw half as many units to get the exact same milligram dose

GLP-1 stands for Glucagon-Like Peptide-1. This hormone is made naturally by your gut

Strategic Implications for Stakeholders For Biopharma and Biotech Strategic decision-making is more critical than ever